Gentibio, Inc.

Publicly observed

Cambridge, United States

Seen in a public record (e.g. a government grant database); not otherwise verified.

Details and provenance

Item	Value	Source	Status
Country	US	NIH RePORTER (opens in a new tab) 28 Sept 2026	Publicly observed
City / locality	Cambridge	NIH RePORTER (opens in a new tab) 28 Sept 2026	Publicly observed
Name	Gentibio, Inc.	NIH RePORTER (opens in a new tab) 28 Sept 2026	Publicly observed
UEI (U.S. federal entity ID)	HNHTFLZ9U5D4	NIH RePORTER (opens in a new tab) 28 Sept 2026	Publicly observed

Grant17 Sept 2026Publicly observed
NIH SBIR/STTR award: An allogeneic and gut specific Engineered T regulatory cell therapy for the treatment of Inflammatory Bowel Disease
USD 1,061,227.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
Grant7 Sept 2026Publicly observed
NIH SBIR/STTR award: Engineered Tissue Treg Therapy for the Treatment of ALS
USD 320,037.00 · National Institute of Neurological Disorders and Stroke · Source: NIH RePORTER (opens in a new tab)
Grant24 Aug 2026Publicly observed
NIH SBIR/STTR award: GNTI-148: an allogeneic islet-specific engineered Treg for treating T1D
USD 1,066,332.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
Grant15 Aug 2025Publicly observed
NIH SBIR/STTR award: Development of Tissue Engineered Tregs as a Treatment for Acute Ischemic Stroke
USD 1,150,749.00 · National Institute of Neurological Disorders and Stroke · Source: NIH RePORTER (opens in a new tab)
Grant15 Aug 2025Publicly observed
NIH SBIR/STTR award: Development of Tissue Engineered Tregs as a Treatment for Acute Ischemic Stroke
USD 1,150,417.00 · National Institute of Neurological Disorders and Stroke · Source: NIH RePORTER (opens in a new tab)

Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.